|Bid||0.00 x 1100|
|Ask||0.00 x 800|
|Day's range||62.19 - 65.79|
|52-week range||25.31 - 141.01|
|Beta (5Y monthly)||N/A|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Vir Biotechnology (NASDAQ: VIR) and GlaxoSmithKline (NYSE: GSK) have gone from dating to a full-blown relationship in under a year. As part of the deal, GlaxoSmithKline took a $250 million stake in Vir. The giant British drugmaker must have liked what it saw in the American biotech because it is expanding its relationship with Vir to include treatments for influenza.
Shares of Vir Biotechnology (NASDAQ: VIR) were 12.6% higher as of 12:47 p.m. EST on Wednesday. The big gain came after Vir and GlaxoSmithKline (NYSE: GSK) announced that they're expanding their collaboration to include the development of therapies targeting influenza and other respiratory viruses. Last year, Vir and GlaxoSmithKline teamed up to develop therapies targeting coronaviruses, including the one that causes COVID-19.
Lilly (LLY) collaborates with Vir and Glaxo to develop its COVID-19 therapy, bamlanivimab, in combination with their COVID-19 antibody candidate.